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Background: To determine whether psychotropic cessation in patients with drug-induced 
blepharospasm improves motor symptoms.
Methods: In patients with drug-induced blepharospasm, we withdrew part or all of their psy-
chotropic medication and assessed motor symptoms using the Jankovic rating scale (0 = none, 
1 = noticeable, 2 = mild, 3 = moderate, 4 = severe) at first presentation and after cessation.
Results: Twelve patients (eleven women and one man, mean age 60.4 years) were enrolled. 
Psychotropics were administered before the onset of blepharospasm in all patients. The mean 
duration of treatment with psychotropic medication was 47.3 (range 3–120) months. Jankovic 
rating scale at initial presentation was 3 in eleven patients and 2 in one patient. After cessation, 
blepharospasm started to improve in all cases within 2 months (average 3.9 weeks). While the 
effect of psychotropic cessation was variable, the symptoms eventually improved to more than 
2 on the rating scale. Three of the twelve patients underwent a single botulinum neurotoxin 
injection and were withdrawn from therapy after cessation.
Conclusion: Psychotropic drugs can cause blepharospasm in some cases. Clinicians should 
consider reducing psychotropic medication as far as possible in patients with blepharospasm 
taking these agents.
Keywords: drug-induced, tardive, blepharospasm, antipsychotic, dose reduction, 
benzodiazepine
Introduction
Blepharospasm is a form of focal dystonia characterized by three major symptoms, ie, 
motor symptoms (difficulty keeping the eyes open and excessive blinking),   sensory 
symptoms (irritation of the eyes and photophobia), and psychiatric symptoms (depres-
sion and anxiety).1,2 The disorder is rarely self-limiting and generally is a lifelong 
disability.3
Blepharospasm can be classified into three groups, ie, essential, secondary, and drug-
induced. Drug-induced blepharospasm is most commonly associated with neuroleptics, as 
well as dopaminergic agents, antihistamines, calcium channel blockers, and noradrenaline 
and serotonin reuptake inhibitors.4 Additionally, we have shown that benzodiazepines 
and thienodiazepines can often induce blepharospasm.5 We report here twelve cases of 
drug-induced blepharospasm that improved after psychotropic cessation.
Methods
Patients were recruited from the Division of Neuro-Ophthalmology at Inouye Eye 
Hospital, Japan, between 2004 and 2009. Patients were included in the study if they Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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had been on psychotropic medication that started after the 
onset of blepharospasm. Exclusion criteria were: refusal of 
consent to enrollment after being informed about the risks 
and benefits of psychotropic cessation; decision not to cease 
the drug or reduce the dose following communication with 
psychiatrists; lack of follow-up for at least 6 months after 
cessation; presence of motor symptoms from other move-
ment disorders, including Parkinsonism, dyskinesia, and 
akathisia; and presence of major psychiatric diseases, such as 
bipolar disorder or schizophrenia that required psychotropic 
medication to be used.
Patients who met the selection criteria were enrolled 
consecutively. After obtaining informed consent from the 
patients, and permission from the psychiatrists or internists 
who prescribed the patient’s medication, we gradually reduced 
the dose of the psychotropics. During dose reduction, patients 
were closely monitored by their neuro-ophthalmologists and 
psychiatrists. The study was approved by the institutional 
ethics committee.
The motor symptoms of blepharospasm were assessed 
using the Jankovic rating scale, whereby 0 = none, 1 = notice-
able, 2 = mild, 3 = moderate, and 4 = severe, at the initial 
presentation and during dose reduction.6 We performed a final 
symptom assessment using the same scale at least 6 months 
after we completed psychotrophic cessation.
We also obtained information for each patient, including 
age, gender, family history, past medical history, pharmaco-
logical history, the time interval between onset of symptoms 
and when the patients were diagnosed as having blephar-
ospasm, the time interval between when the psychotropic 
medication was initiated and when we started to reduce the 
dose, and the psychiatric diagnoses for which the psychotrop-
ics were prescribed.
Results
Of 138 patients with drug-induced blepharospasm, twelve 
consecutive patients who met the criteria were enrolled 
(eleven females and one male, Table 1). There were no 
patients who had a significant family history, previous 
neurological disorder, or any other movement disorders 
except for blepharospasm. No patients received any other 
therapies that may have influenced central nervous system 
function, including hormone replacement therapy. Mean 
age of the 12 patients was 60.4 years, with a range of 
36–76 years (Table 2). The mean time interval from the 
onset of blepharospasm to when the diagnosis was made 
was 10.8 (range 1–42) months. The Jankovic rating scale 
at the initial presentation was 3 in eleven patients and 2 in 
one patient. The final Jankovic rating after psychotrophic 
cessation was 1 in four patients and 0 in eight patients. The 
difference in rating on the scale between the initial and final 
assessment was 3 in seven patients and 2 in five patients. 
The most commonly prescribed psychotropics withdrawn 
were etizolam (five patients) followed by brotizolam, alpra-
zolam, and zolpidem (one patient each). The mean duration 
of treatment with psychotropic medication was 47.3 (range 
3–120) months. The psychiatric diagnoses were insomnia 
(eleven patients), depression (seven patients), and anxiety 
(six patients). On average, symptoms started to improve 
3.9 weeks after cessation (range 1–8 weeks). While the 
effect of psychotropic cessation was variable, the symptoms 
eventually improved to more than 2 on the rating scale, with 
67% (8/12) of the patients completely recovering.
Cases 10, 11, and 12 received botulinum neurotoxin injec-
tion therapy (Table 1, Figure 1). Cases 10 and 11 received the 
injection after dose reduction was started, while case 12 had   
an injection prior to dose reduction. These three cases 
improved after receiving a single injection, and therefore   
decided to stop therapy once dose reduction was completed.
Case presentation
A 57-year-old woman (case 7 in Table 1) presented with a 
2-year history of difficulty keeping her eyes open, excessive 
blinking, eye irritation, and photophobia. For the previous 
3 years and 9 months, she had been continuously treated 
with etizolam 4 mg/day for insomnia and anxiety. After 
16–18 months of medication, she felt marked fatigue of her 
eyes. Voluntary closure of the eyes and sleep relieved this 
symptom. She tried to avoid sunlight and wind because of 
eye irritation. Her friends could not understand why she 
could not open her eyes and she began to avoid company. 
These symptoms made her more nervous and her insomnia 
got worse.
She consulted an ophthalmologist about her eye problem 
and was diagnosed as having “dry eye”. The eye irritation 
did not improve even though she received treatment for it. 
Another ophthalmologist’s review revealed no local pathol-
ogy and her symptoms were thought to be of psychosomatic 
origin. Blinking became more troublesome approximately 
6 months before presentation to our unit. Her psychiatrist 
noticed her symptoms at routine follow-up and referred her 
to our eye hospital.
On examination, she was noted to have excessive blink-
ing and bilateral involuntary spasms of the orbicularis oculi 
muscles leading to partial eye closure lasting a few seconds. 
Other disorders, such as hemifacial spasm, myokymia, Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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Table 2 Overview of the twelve patients
Mean age 60.4 (36–76)
Sex 11 F and 1 M
Mean duration from the onset of blepharospasm to when the diagnosis was made (months) 10.8 (1–42)
Jankovic rating scale* at the initial presentation 3:11 pts, 2:1pt
Jankovic rating scale* after the dose reduction 1:4 pts, 0:8 pts
Difference of the scale above 3:7 pts, 2:5 pts
The most prescribed psychotropics Etizolam brotizolam alprazolam zolpidem
Mean period of psychotropic medication (months) 47.3 (3–120)
Mean duration from the dose reduction to the improvement of blepharospasm (weeks) 3.9 (1–8)
Notes: *There was no dominant side. Severity of blepharospasm was assessed using the rating scale developed by Jankovic: 0; none, 1; noticeable, 2; mild, 3; moderate, 4; severe.6
Abbreviations: F, female; M, male.
apraxia of eyelid opening, and myasthenia gravis, were 
carefully excluded by ancillary testing. There was no signifi-
cant family history, previous neurological disorder, or any 
movement disorders (including Parkinsonism, dyskinesia, 
and akathisia) except for blepharospasm.
A diagnosis of blepharospasm caused by psychotropic 
medication was made. The Jankovic rating scale at initial 
presentation was 3, ie, moderate in severity. We started to 
reduce to half dose in collaboration with her psychiatrist. 
During dose reduction, the patient was closely monitored by 
neuro-ophthalmologists and psychiatrists, and we evaluated 
her motor symptoms of blepharospasm using the Jankovic 
rating scale. Eight weeks later, she noticed she could open her 
eyes more easily than before. She experienced a temporary 
worsening of her insomnia, and the extent of her excessive 
blinking fluctuated depending on the day. Other treatments 
were not necessary because the symptom gradually improved 
after psychotropic reduction. Etizolam was gradually with-
drawn 2 months after the start of dose reduction. One month 
after cessation, she was almost free from blepharospasm and 
the Jankovic scale rating was improved to 1, ie, noticeable 
in severity.
Discussion
There were no patients affected by major psychosis in the 
current study, and all patients enrolled had only mild psy-
chotic problems, such as anxiety, insomnia, or depression. 
Patients were on various benzodiazepines (alprazolam, 
bromazepam, clonazepam, diazepam, ethyl loflazepate, or 
triazolam) and thienodiazepines (brotizolam, clotiazepam, or 
etizolam), which are widely prescribed in Japan, primarily 
for insomnia and anxiety. The most commonly prescribed 
psychotropic agent was etizolam, a thienodiazepine deriva-
tive and a popular anxiolytic, with a high affinity for ben-
zodiazepine receptors. We have previously reported that 
benzodiazepine and thienodiazepine can cause drug-induced 
blepharospasm, with early cessation of the drugs resulting in 
the relief of the motor symptoms of blepharospasm.5
In all cases in the current study, blepharospasm started 
to improve within 2 months (mean 3.9, range 1–8 weeks) 
Time after psychotropic cessation (weeks)
0
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Figure 1 Clinical course of twelve cases of psychotrophic-induced blepharospasm. After cessation, symptoms started to improve in 3.9 weeks on average (range 1–8 weeks). 
While the effect of the cessation was variable, symptoms improved to more than 2 on the Jankovic scale within 2 months in all cases.
Notes: The underlined number in italics indicates the case number.
*Cases 10 and 11 received a single botulinum neurotoxin injection 4 weeks after psychotropic cessation (), and Case 12 received an injection 8 weeks before the cessation. Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
13
Blepharospasm after psychotropic cessation
after   cessation. While the effect of psychotropic cessation 
was variable, symptoms eventually improved to more than 
2 on the rating scale. Moreover, psychotropic cessation led 
to improvement, with complete reversal in eight of twelve 
patients (67%).
Cases 10, 11, and 12 underwent botulinum neurotoxin 
injection therapy. Cases 10 and 11 received the injection 
after dose reduction had started, while Case 12 received an 
injection before dose reduction. After cessation, these three 
cases started to improve at weeks 3, 8, and 4, respectively. 
Their symptoms improved to more than 2 on the rating 
scale. Botulinum neurotoxin injection therapy has been 
shown to improve the motor symptoms of blepharospasm,3 
so improvement in these cases was due to both psychotro-
pic cessation and injection therapy. However, the beneficial 
effect of botulinum neurotoxin is transient. While these 
three patients only received one injection, they did show 
improvement after psychotropic cessation and no longer 
needed injection therapy 1 year after cessation. In the other 
nine cases, results were similar, with symptoms starting 
to improve within 2 months of cessation (mean 3.6, range 
1–8 weeks). Although our results indicate that psychotropic 
cessation may have had a greater effect in three cases, we 
could not determine whether botulinum neurotoxin injec-
tion prompted the recovery or whether it was psychotropic 
cessation that assisted in resolution of the drug-induced 
blepharospasm.
While psychotropic reduction or cessation would seem 
to be a logical first step in the management of tardive dys-
tonia and drug-induced blepharospasm, this is not always 
possible in a clinical setting because of the overriding need 
to manage current psychotic symptoms and/or reduce the 
risk of relapse.7 We previously showed that there was a high 
incidence (68%) of mood disorders in patients with possible 
drug-induced blepharospasm when using the Center for 
Epidemiologic Studies Depression Scale, while there was a 
32% incidence in drug-free blepharospasm versus 16% in 
healthy controls.8 Thus, there is certainly a risk of depression 
or mood disorders when blepharospasm is present. Therefore, 
in patients being treated with minor tranquilizers for mild 
mental illnesses, such as anxiety or insomnia, psychotropic 
use should be reduced or discontinued in cases where there 
is presumed drug-induced blepharospasm.
Although the pathogenesis of drug-induced blepharos-
pasm is not known, abnormalities of the cortical or subcorti-
cal neural pathways have been suggested.9 With regard to 
neuroleptics, it has been theorized that the likely mechanism 
is supersensitivity of striatal dopamine receptors, although 
this hypothesis has been extensively debated.10 Chronic use 
of these agents may lead to alteration of the normal balance 
between D1 and D2 receptors, which could cause striatal 
disinhibition of the thalamocortical pathway and consequent 
dystonia.11 A previous positron emission tomography study 
suggested that decreased dopamine D2 receptor binding may 
be one of the predisposing factors leading to dysfunction 
of the motor circuit, resulting in loss of broad inhibition 
of unwanted movements during an intended movement in 
blepharospasm patients.12 Unfortunately, these hypotheses 
do not address what is responsible for causing a proportion 
of patients treated with neuroleptics to be vulnerable to the 
development of blepharospasm and other dystonias.11
In conclusion, psychotropic medication can effectively 
control psychiatric symptoms and so has been widely used. 
However, these drugs can not only cause blepharospasm, 
but may also exacerbate symptoms. In this study, while the 
effect of psychotropic reduction or cessation in cases of 
drug-induced blepharospasm was variable, all cases even-
tually started to show improvement of symptoms within 
2 months. Patients with blepharospasm are occasionally 
treated with neuroleptics and/or anxiolytics. These agents 
may be responsible for underlying mental disorders or 
psychiatric symptoms associated with blepharospasm. 
Clinicians should consider reducing psychotropic medica-
tions, provided the clinical situation permits such a course 
of action in their patients.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Hall TA, McGwin G Jr, Searcey K, Xie A, Hupp SL, Kline LB. Health-
related quality of life and psychosocial characteristics of patients 
with benign essential blepharospasm. Arch Ophthalmol. 2006;124(1): 
116–119.
2.  Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: 
Report from the BEBRF International Workshop. Neurology. 2008; 
71(16):1275–1282.
3.  Hallett M. Blepharospasm: Recent advances. Neurology. 2002; 
59(9):1306–1312.
4.  Lee Y, Yeh WC, Chong MY, Lin PY, Chang YY. Venlafaxine and tar-
dive blepharospasm: A case report. Prog Neuropsychopharmacol Biol 
Psychiatry. 2007;31(5):1139–1140.
5.  Wakakura M, Tsubouchi T, Inouye J. Etizolam and benzodiazepine 
induced blepharospasm. J Neurol Neurosurg Psychiatry. 2004; 
75(3):506–507.
6.  Jankovic J, Orman J. Botulinum A toxin for cranial cervical 
dystonia: A double-blind, placebo-controlled study. Neurology. 1987; 
37(4):616–623.
7.  Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation 
and neuroleptics as specific treatments for tardive dyskinesia. Cochrane 
Database Syst Rev. 2006;(1):CD000459.
8.  Wakakura M. Nascent psychosomatic medicine in ophthalmology. Jpn 
J Psychosom Med. 2010;50(1):37–42.Drug, Healthcare and Patient Safety
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-healthcare-and-patient-safety-journal
Drug, Healthcare and Patient Safety is an international, peer-reviewed 
open-access journal exploring patient safety issues in the healthcare 
continuum from diagnostic and screening interventions through to treat-
ment, drug therapy and surgery. The journal is characterized by the rapid 
reporting of reviews, original research, clinical, epidemiological and 
post-marketing surveillance studies, risk management, health literacy 
and educational programs across all areas of healthcare delivery. The 
manuscript management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
14
Emoto et al
  9.  Mauriello JA Jr, Carbonaro P , Dhillon S, Leone T, Franklin M. Drug-associated 
facial dyskinesias. A study of 238 patients. J Neuroophthalmology. 
1998;18(2):153–157.
  10.  Jankovic J. Tardive syndromes and other drug-induced movement 
disorders. Clin Neuropharmacol. 1995;18(3):197–14.
  11.  Sachdev P. Tardive blepharospasm. Mov Disord. 1998;13(6): 
947–951.
  12.  Horie C, Suzuki Y, Kiyosawa M, et al. Decreased dopamine D recep-
tor binding in essential blepharospasm. Acta Neurol Scand. 2009; 
119(1):49–54.